Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Yoshiki Nakae"'
Autor:
Sumiyuki Nishida, Soyoko Morimoto, Yusuke Oji, Satoshi Morita, Toshiaki Shirakata, Takayuki Enomoto, Akihiro Tsuboi, Yutaka Ueda, Kiyoshi Yoshino, Alzaaqi Shouq, Mizuki Kanegae, Satoshi Ohno, Fumihiro Fujiki, Hiroko Nakajima, Yoshiki Nakae, Jun Nakata, Naoki Hosen, Atsushi Kumanogoh, Yoshihiro Oka, Tadashi Kimura, Haruo Sugiyama
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Supplemental Digital Content is available in the text.
The HLA-A*24:02–restricted peptide vaccine targeting Wilms’ tumor 1 (WT1) (WT1 vaccine) is a promising therapeutic strategy for ovarian cancer; however, its efficacy varies among patient
The HLA-A*24:02–restricted peptide vaccine targeting Wilms’ tumor 1 (WT1) (WT1 vaccine) is a promising therapeutic strategy for ovarian cancer; however, its efficacy varies among patient
Autor:
Takahiro Karasuno, Hiroyuki Sugahara, Tsuyoshi Kamae, Yuma Tada, Shuji Ueda, Norimitsu Saito, Toru Kida, Satoru Kosugi, Hirohiko Shibayama, Hideki Mitsui, Jun Ishikawa, Manabu Kawakami, Yasuhiko Azenishi, Yozo Uchida, Tetsuhisa Kitamura, Yasuhiro Moriyama, Ruri Kato, Shigeo Fuji, Masashi Nakagawa, Ryoto Sakaniwa, Yoshiki Nakae, Masato Iida, Kenji Nozaki, Hiroaki Masaie
Publikováno v:
Leukemialymphoma. 61(9)
This retrospective, multicenter observational study investigated the prognostic value of pretreatment serum soluble interleukin-2 receptor (sIL-2R) level for outcomes of newly diagnosed follicular lymphoma (FL) grade 1-3a who required treatment at di
Autor:
Yuji Seo, Hiroshi Abe, Yoshihiro Tanaka, Yoshiki Nakae, Manabu Kawakami, Takero Hirata, Kazuhiko Ogawa, Shintaro Maruoka, Yuichi Akino, Keisuke Tamari, Fumiaki Isohashi, Katsuyuki Yano
Publikováno v:
Journal of Radiation Research
The goal of total body irradiation (TBI) is to deliver a dose to the whole body with uniformity within ±10%. The purpose of this study was to establish the technique of TBI using plastic bead bags. A lifting TBI bed, Model ORP-TBI-MN, was used. The
Autor:
Junichi Sakamoto, Satoshi Morita, Yoshihiro Oka, Atsushi Kumanogoh, Yoshito Takeda, Yasushi Shintani, Manabu Kawakami, Naoki Hosen, Soyoko Morimoto, Miki Iwai, Takashi Kijima, Yui Murakami, Toshiaki Shirakata, Haruo Sugiyama, Yoshiki Nakae, Masayoshi Inoue, Mari Fukuda, Hiroko Nakajima, Takuya Harada, Kana Hasegawa, Sumiyuki Nishida, Satoshi Takashima, Akihiro Tsuboi, Hiroshi Kida, Fumihiro Fujiki, Yusuke Oji, Jun Nakata, Meinoshin Okumura, Eiichi Morii
Publikováno v:
International Journal of Cancer. 142:2375-2382
Thymic epithelial tumors are rare malignancies, and no optimal therapeutic regimen has been defined for patients with advanced disease. Patients with advanced thymic epithelial tumors, which were resistant or intolerable to prior therapies, were elig
Autor:
Yoshihiro Oka, Yoshiki Nakae, Haruo Sugiyama, Akihiro Tsuboi, Naoki Hosen, Daisuke Motooka, Fumihiro Fujiki, Yusuke Oji, Jun Nakata, Sumiyuki Nishida, Hiroko Nakajima, Soyoko Morimoto, Atsushi Kumanogoh, Manabu Kawakami, Kana Hasegawa
Publikováno v:
British Journal of Haematology. 182:287-290
Autor:
Yoshiki Nakae, Akiko Fukunaga, Yoshitomo Maesako, Nobuyoshi Arima, Yuta Terada, Toshinari Nakane, Kenichi Komatsu, Wataru Kishimoto, Osamu Higuchi, Sumie Tabata, Mizuki Hyuga
Publikováno v:
Internal Medicine
Autoimmune autonomic ganglionopathy is an autonomic disorder that occurs as a symptom of paraneoplastic neurological syndrome. To date, there have been no reports on multiple myeloma with autoimmune autonomic ganglionopathy. A 37-year-old Japanese wo
Autor:
Mayuko Adachi, Miki Iwai, Naoki Hosen, Satoshi Morita, Junichi Sakamoto, Yusuke Oji, Yoshihiro Oka, Yoshiki Nakae, Naoya Hashimoto, Toshiki Yoshimine, Hiroko Nakajima, Yui Murakami, Fumihiro Fujiki, Masahiro Iwamoto, Yasuyoshi Chiba, Manabu Kawakami, Ryo Ichinohasama, Sumiyuki Nishida, Akihiro Tsuboi, Soyoko Morimoto, Olga A. Elisseeva, Satoshi Takashima, Shuichi Izumoto, Jun Nakata, Naoki Kagawa, Haruo Sugiyama
Publikováno v:
International Journal of Cancer
We previously evaluated Wilms’ tumor gene 1 (WT1) peptide vaccination in a large number of patients with leukemia or solid tumors and have reported that HLA‐A*24:02 restricted, 9‐mer WT1‐235 peptide (CYTWNQMNL) vaccine induces cellular immune
Autor:
Yoshiaki Yuba, Toshiyuki Kitano, Nobuyoshi Arima, Yoko Takiuchi, Akiko Fukunaga, Wataru Kishimoto, Yoshiki Nakae, Naomi Matsuzaki, Sumie Tabata
Publikováno v:
International journal of hematology. 109(4)
Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of peripheral T-cell lymphoma with an aggressive clinical course and poor prognosis after conventional chemotherapy, for which there is no current standard of care. We describe here an 87-
Autor:
Haruo Sugiyama, Yoshiki Nakae, Jun Nakata, Naoki Hosen, Yusuke Oji, Akihiro Tsuboi, Tetsuo Maeda, Yoshiko Hashii, Satoshi Takashima, Yoshihiro Oka, Sumiyuki Nishida, Atsushi Kumanogoh
Publikováno v:
Expert Review of Hematology. 7:671-681
Allogeneic hematopoietic stem cell transplantation (HSCT) has largely improved the prognosis of leukemia patients. However, relapse is still a major concern. One promising option for the prevention of relapse is vaccination therapy. The post allogene
Autor:
Soyoko Morimoto, Yutaka Takeda, Toru Kitagawa, Satoru Yanagisawa, Masaki Mori, Akitaka Takahara, Toshio Tanaka, Toshinori Ito, Atsushi Kumanogoh, Hiroshi Wada, Naoki Hosen, Hiroaki Nagano, Hideo Komita, Hidetoshi Eguchi, Shigeo Koido, Haruo Sugiyama, Yoichi Toyama, Yusuke Oji, Sumiyuki Nishida, Yoshihiro Oka, Jun Nakata, Yuichiro Doki, Akihiro Tsuboi, Satoshi Morita, Toshifumi Ohkusa, Yoshiki Nakae, Hisao Tajiri, Masahiro Ikegami, Ichiro Kawase, Sadamu Homma, Junichi Sakamoto, Kazuma Hara
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Supplemental Digital Content is available in the text.
Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy. We aimed to investigate the feasibility of a combination therapy consisting of gemcitabine and WT1 peptide–
Wilms tumor gene (WT1) protein is an attractive target for cancer immunotherapy. We aimed to investigate the feasibility of a combination therapy consisting of gemcitabine and WT1 peptide–